Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2652-2663

  Webb, Brandon J ^a   Dascomb, Kristin ^a   Stenehjem, Edward ^a   Vikram, Holenarasipur R ^b   Agrwal, Neera ^b   Sakata, Kenneth ^b   Williams, Kathryn ^b   Bockorny, Bruno ^c   Bagavathy, Kavitha ^c   Mirza, Shireen ^c   Metersky, Mark ^c   Deanh, Nathan C ^d  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CORTICOSTEROID; DOXYCYCLINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; LEVOFLOXACIN; MACROLIDE; PREDNISONE; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BORDETELLA PERTUSSIS; BREATHING RATE; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR DISEASE; CHLAMYDIA PNEUMONIAE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; COUGHING; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG IN PNEUMONIA CLINICAL PREDICTION SCORE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FALSE POSITIVE RESULT; FLU LIKE SYNDROME; HAEMOPHILUS INFLUENZAE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LIVER DISEASE; MAJOR CLINICAL STUDY; MECHANICAL VENTILATOR; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NEUTROPHIL COUNT; NONHUMAN; OXYGEN SATURATION; PREDICTIVE VALUE; PREVOTELLA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS ANGINOSUS; VEILLONELLA; AGED; FEMALE; GENETICS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84964978311     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03071-15     Document Type: Article

References (60)

1. Buie VC, Owings MF, DeFrances CJ, Golosinskiy A. 2010. National Hospital Discharge Survey: 2006 summary. Vital Health Stat 13 2010:1-79.
2. Heron M, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. 2009. Deaths: final data for 2006. Natl Vital Stat Rep 57:1-134.
3. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, Imaizumi K, Sato T, Hasegawa Y. 2009. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 135:633-640. http://dx.doi.org/10.1378/chest.08-1357.
4. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. 2008. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 134:963-968. http://dx.doi.org/10.1378/chest.08-0842.
5. Dean NC, Bateman KA, Donnelly SM, Silver MP, Snow GL, Hale D. 2006. Improved clinical outcomes with utilization of a communityacquired pneumonia guideline. Chest 130:794-799. http://dx.doi.org/10 .1378/chest.130.3.794.
6. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. 2009. Guidelineconcordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 169:1525-1531. http://dx.doi.org/10.1001/archinternmed.2009.259.
7. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27-S72. http://dx.doi.org/10.1086/511159.
8. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. 2005. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128: 3854-3862. http://dx.doi.org/10.1378/chest.128.6.3854.
9. American Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. http://dx.doi.org/10.1164/rccm.200405-644ST.
10. Berger A, Edelsberg J, Oster G, Huang X, Weber DJ. 2014. Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.AmJ Med Sci 347:347-356. http://dx.doi.org/10.1097 /MAJ.0b013e318294833f.
11. Jones BE, Jones M, Huttner B, Stoddard G, Brown KA, Stevens V, Greene T, Sauer B, Madaras-Kelly K, Rubin M, Goetz MB, Samore M. 2015. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 61:1403-1410. http://dx.doi.org/10.1093/cid/civ629.
12. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, Anzueto A, Mortensen EM. 2011. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 38:878-887. http://dx.doi.org/10.1183/09031936.00141110.
13. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. 2011. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 11:181-189. http://dx.doi.org/10.1016/S1473-3099(10)70314-5.
14. Troitino AX, Porhomayon J, El-Solh AA. 2013. Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis. Lung 191:229-237. http://dx.doi.org/10.1007 /s00408-013-9462-8.
15. Chalmers JD, Rother C, Salih W, Ewig S. 2014. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58:330-339. http://dx .doi.org/10.1093/cid/cit734.
16. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, Kalil AC. 2014. Epidemiology and predictors of multidrugresistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 58:5262-5268. http://dx.doi.org/10.1128 /AAC.02582-14.
17. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. 2011. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 53:107-113. http://dx.doi.org/10.1093/cid/cir274.
18. Chen JI, Slater LN, Kurdgelashvili G, Husain KO, Gentry CA. 2013. Outcomes of health care-associated pneumonia empirically treated with guidelineconcordant regimens versus community-acquired pneumonia guidelineconcordant regimens for patients admitted to acute care wards from home. Ann Pharmacother 47:9-19. http://dx.doi.org/10.1345/aph.1R322.
19. El Solh AA, Akinnusi ME, Alfarah Z, Patel A. 2009. Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing homeacquired pneumonia. J Am Geriatr Soc 57:1030-1035. http://dx.doi.org /10.1111/j.1532-5415.2009.02279.x.
20. Taylor SP, Taylor BT. 2013. Health care-associated pneumonia in haemodialysis patients: clinical outcomes in patients treated with narrow versus broad spectrum antibiotic therapy. Respirology 18:364-368. http://dx .doi.org/10.1111/j.1440-1843.2012.02306.x.
21. Burgess LD, Drew RH. 2014. Comparison of the incidence of vancomy- cin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34:670-676. http: //dx.doi.org/10.1002/phar.1442.
22. Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA. 2014. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillintazobactam or cefepime. Pharmacotherapy 34:662-669. http://dx.doi.org /10.1002/phar.1428.
23. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. 2007. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29:1107-1115. http://dx.doi.org/10 .1016/j.clinthera.2007.06.014.
24. Meaney CJ, Hynicka LM, Tsoukleris MG. 2014. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34:653-661. http://dx.doi.org/10.1002/phar .1423.
25. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH. 2010. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 65:608-618. http://dx.doi.org/10.1093/jac/dkq038.
26. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. 2010. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 340:c2096. http: //dx.doi.org/10.1136/bmj.c2096.
27. Aliberti S, Zanaboni AM, Blasi F. 2012. Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores. Clin Infect Dis 54:1519-1520. http://dx.doi.org/10.1093/cid /cis260.
28. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. 2004. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 39:474-480. http://dx.doi.org/10.1086 /422317.
29. Madaras-Kelly KJ, Remington RE, Fan VS, Sloan KL. 2012. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med 7:195-202. http://dx.doi.org/10.1002/jhm.942.
30. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, Yuda H, Yoshida M, Kobayashi H, Taguchi O, Gabazza EC, Takei Y, Miyashita N, Ihara T, Brito V, Niederman MS. 2013. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 57:1373-1383. http://dx.doi.org/10 .1093/cid/cit571.
31. Park SC, Kim EY, Kang YA, Park MS, Kim YS, Kim SK, Chang J, Jung JY. 2013. Validation of a scoring tool to predict drug-resistant pathogens in hospitalised pneumonia patients. Int J Tuberc Lung Dis 17:704-709. http://dx.doi.org/10.5588/ijtld.12.0723.
32. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y. 2013. Risk factors for drug-resistant pathogens in community-acquired and healthcare- associated pneumonia. Am J Respir Crit Care Med 188:985-995. http://dx.doi.org/10.1164/rccm.201301-0079OC.
33. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. 2008. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 168:2205-2210. http: //dx.doi.org/10.1001/archinte.168.20.2205.
34. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. 2015. Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. Acad Emerg Med 22:730-740. http://dx.doi.org/10.1111/acem.12672.
35. Dean NC, Jones BE, Ferraro JP, Vines CG, Haug PJ. 2013. Performance and utilization of an emergency department electronic screening tool for pneumonia. JAMA Intern Med 173:699-701. http://dx.doi.org/10.1001 /jamainternmed.2013.3299.
36. Bartlett R. 1974. Medical microbiology: quality cost and clinical relevance. John Wiley & Sons, Inc., New York, NY.
37. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH. 2012. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54:193-198. http://dx.doi.org/10 .1093/cid/cir813.
38. Schreiber MP, Chan CM, Shorr AF. 2010. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 137:1283-1288. http://dx.doi.org/10.1378/chest.09-2434.
39. Wooten DA, Winston LG. 2013. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospitalonset pneumonia. Respir Med 107:1266-1270. http://dx.doi.org/10.1016 /j.rmed.2013.05.006.
40. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. 2013. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 13:268. http://dx.doi.org/10.1186/1471-2334-13-268.
41. Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, Kang YA. 2011. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis 11:61. http://dx.doi.org/10.1186 /1471-2334-11-61.
42. Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menendez R, Mensa J, Torres A. 2015. Risk factors associated with potentially antibiotic-resistant pathogens in community- acquired pneumonia. Ann Am Thorac Soc 12:153-160. http://dx .doi.org/10.1513/AnnalsATS.201407-305OC.
43. Venditti M, Falcone M, Corrao S, Licata G, Serra P. 2009. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 150:19-26. http://dx .doi.org/10.7326/0003-4819-150-1-200901060-00005.
44. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. 2012. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 54:470-478. http://dx.doi .org/10.1093/cid/cir840.
45. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. 2013. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 68:997-999. http://dx.doi.org/10.1136/thoraxjnl-2013-203384.
46. Filius PM, Gyssens IC, Kershof IM, Roovers PJ, Ott A, Vulto AG, Verbrugh HA, Endtz HP. 2005. Colonization and resistance dynamics of Gram-negative bacteria in patients during and after hospitalization. Antimicrob Agents Chemother 49:2879-2886. http://dx.doi.org/10.1128 /AAC.49.7.2879-2886.2005.
47. Fisch J, Lansing B, Wang L, Symons K, Cherian K, McNamara S, Mody L. 2012. New acquisition of antibiotic-resistant organisms in skilled nursing facilities. J Clin Microbiol 50:1698-1703. http://dx.doi.org/10.1128 /JCM.06469-11.
48. Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR. 2012. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare- associated pneumonia. Respir Med 106:1606-1612. http://dx.doi .org/10.1016/j.rmed.2012.08.003.
49. Jones BE, Jones J, Bewick T, Lim WS, Aronsky D, Brown SM, Boersma WG, van der Eerden MM, Dean NC. 2011. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 140:156-163. http://dx.doi.org/10.1378/chest.10-1296.
50. Dangerfield B, Chung A, Webb B, Seville MT. 2014. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 58:859-864. http://dx.doi.org/10.1128/AAC.01805-13.
51. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. 2001. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 32:1393-1398. http://dx.doi.org/10.1086/320151.
52. Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857-872. http://dx .doi.org/10.1002/(SICI)1097-0258(19980430)17:8-857::AID-SIM777 -3.0.CO;2-E.
53. Hanley JA, McNeil BJ. 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36. http: //dx.doi.org/10.1148/radiology.143.1.7063747.
54. Brito V, Niederman MS. 2009. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 22:316-325. http://dx.doi.org/10.1097/QCO.0b013e328329fa4e.
55. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250. http://dx.doi.org/10.1056/NEJM199701233360402.
56. Goldstein RC, Husk G, Jodlowski T, Mildvan D, Perlman DC, Ruhe JJ. 2014. Fluoroquinolone- and ceftriaxone-based therapy of communityacquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms. Am J Infect Control 42:539-541. http://dx.doi.org/10.1016/j.ajic.2014.01.005.
57. Kuster SP, Rudnick W, Shigayeva A, Green K, Baqi M, Gold WL, Lovinsky R, Muller MP, Powis JE, Rau N, Simor AE, Walmsley SL, Low DE, McGeer A, Toronto Invasive Bacterial Diseases Network. 2014. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis 59:944-952. http://dx.doi.org/10.1093/cid/ciu497.
58. Metersky M, Frei CR, Mortensen EM. 2015. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 21:157-163. http: //dx.doi.org/10.1111/resp.12651.
59. Boyce JM, Pop OF, Abreu-Lanfranco O, Hung WY, Fisher A, Karjoo A, Thompson B, Protopapas Z. 2013. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillinresistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother 57:1163-1168. http://dx.doi.org/10 .1128/AAC.01965-12.
60. TDR Diagnostics Evaluation Expert Panel, Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N, Wongsrichanalai C, Linke R, O'Brien R, Perkins M, Cunningham J, Matsoso P, Nathanson CM, Olliaro P, Peeling RW, Ramsay A. 2010. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 8:S17-S29.